ELIC — Elicera Therapeutics AB Income Statement
0.000.00%
- SEK45.27m
- SEK4.56m
- SEK11.23m
Annual income statement for Elicera Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | — | SAS | SAS | SAS | SAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.001 | 1.28 | 11.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 0.194 | 2.83 | 13.1 | 20.6 | 28.3 |
Operating Profit | -0.194 | -2.83 | -13.1 | -19.4 | -17.1 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -0.191 | -2.82 | -13.1 | -19.4 | -16.4 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.191 | -2.82 | -13.1 | -19.4 | -16.4 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.191 | -2.82 | -13.1 | -19.4 | -16.4 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -0.191 | -2.82 | -13.1 | -19.4 | -16.4 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.01 | -0.143 | -0.663 | -0.983 | -0.829 |
Dividends per Share |